Ortho Division
Tofarit 5
Tofacitinib 5 mg (Extended Release) Tablets
Need more information?
Our team can help with product and packaging enquiries.
A CLOSER LOOK
Product information.
Product overview
- Second-generation selective Janus kinase (JAK) inhibitor targeting the JAKl enzyme
- Approved by US Food and Drug Administration (FDA), the European Medical Agency (EMA) and National Institute for Health and Care Excellence (NICE)Inhibits progression of structural damage in patients with RA
- Effective in reducing signs and symptoms of disease and improving health-related quality of life (HR-QOL)
- Associated with rapid clinical response (54.2% on day 14) in ulcerative colitis
Specifications
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PA)
- Ulcerative Colitis (UC)
LET’S TALK PRODUCTS
Get the details
you need.
Ask our team about this formulation, packaging, or a business enquiry.
Your enquiry is aboutTofarit 5
CONTINUE EXPLORING
